An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis

Trial Profile

An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 19 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top